173039-10-6 Usage
Uses
2-(Phosphonomethyl)pentanedioic Acid is a selective glutamate carboxypeptidase 2 (GCP-II) inhibitor, the enzyme which catabolizes the abundant neuropeptide N-acetyl-aspartyl-glutamate (NAAG) to N-acetylaspartate (NAA) and glutamate. A posiible target in the treatment of multiple sclerosis and Schizophrenia.
Biological Activity
Highly potent and selective inhibitor of? glutamate carboxypeptidase 2 (GCP II/N-acetylated α -linked dipeptidase/NAALADase) with a K i value of 275 pM. Neuroprotective; protects against glutamate-mediated motor neuron degeneration and reduces volume of injury following middle cerebral artery occlusion (MCAO).
Biochem/physiol Actions
2-PMPA is a potent and selective inhibitor of Glutamate carboxypeptidase II (GCPII).
Check Digit Verification of cas no
The CAS Registry Mumber 173039-10-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,3,0,3 and 9 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 173039-10:
(8*1)+(7*7)+(6*3)+(5*0)+(4*3)+(3*9)+(2*1)+(1*0)=116
116 % 10 = 6
So 173039-10-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H11O7P/c7-5(8)2-1-4(6(9)10)3-14(11,12)13/h4H,1-3H2,(H,7,8)(H,9,10)(H2,11,12,13)
173039-10-6Relevant articles and documents
DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME
-
, (2009/04/24)
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).
Naaladase inhibitors for treating retinal disorders and glaucoma
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
Prodrugs of NAALAdase inhibitors
-
, (2008/06/13)
The present invention relates to prodrugs of NAALADase inhibitors, pharmaceutical compositions comprising the same, and methods of using the same to treat glutamate abnormalities and prostate diseases.
